Cannell & Spears LLC acquired a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 156,746 shares of the life sciences company's stock, valued at approximately $3,555,000. Cannell & Spears LLC owned approximately 0.20% of Integra LifeSciences as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of IART. Principal Financial Group Inc. boosted its position in shares of Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after buying an additional 63,266 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Integra LifeSciences by 824.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock valued at $2,031,000 after acquiring an additional 99,685 shares during the last quarter. Systematic Financial Management LP grew its stake in shares of Integra LifeSciences by 53.9% in the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock worth $11,115,000 after acquiring an additional 214,272 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Integra LifeSciences by 15.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock valued at $17,158,000 after purchasing an additional 125,620 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Integra LifeSciences during the third quarter valued at approximately $198,000. 84.78% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $23.00.
View Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Stock Performance
Integra LifeSciences stock traded down $0.49 during midday trading on Friday, hitting $19.57. The stock had a trading volume of 695,682 shares, compared to its average volume of 1,046,632. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $34.79. The company has a market capitalization of $1.51 billion, a PE ratio of -217.42, a P/E/G ratio of 0.73 and a beta of 1.24. The firm's fifty day moving average is $23.37 and its two-hundred day moving average is $22.30. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm earned $0.89 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.
Integra LifeSciences Company Profile
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Further Reading
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
